

November Phase 2 decision to commit additional funding for the proposals listed in Schedule A

Confirmed 19 November 2010

Decision Point GF/B21/EDP/27:

The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁷

The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

SCHEDULE A *

**Refer to GF/B21/EDP/32 below for a correction to Schedule A for the grants listed at numbers 10 and 11.*

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
1	Nepal, Malaria, Round 7	NEP-708-G06-M	US\$10,676,236	US\$ 9,859,767	Go
2	Iran, Malaria, Round 7	IRN-708-G02-M	US\$4,872,994	US\$ 4,600,968	Go
3	Iran, TB, Round 7	IRN-708-G03-T	US\$9,948,454	US\$ 6,305,126	Go

⁷ The Phase 2 Panel reviewed the Zambia grants in the light of the findings in the recently published OIG audit report of the Country and the measures put forward by the Secretariat to address those findings. Following representations made by the Country Team on its proposed strategy to manage the portfolio of grants in the Country going forward as well as balancing the issues raised by the key weaknesses in grant management and performance by the Principal Recipients, the Phase 2 Panel was able to make the above recommendations to the Board for continued funding in order to find a constructive way forward for the Country.

	Country, Disease, Round	Grant Number(s)	CCM Requested Amount (Incremental in US\$ or Euros)	Recommended Funding Amount (Incremental in US\$ or Euros)	Recommendation Category
4	Sierra Leone, TB, Round 7	SLE-708-G03-T	US\$5,170,647	UD\$ 4,885,388	Conditional Go
5	Sudan, Malaria, Round 7	SUD-708-G09-M	US\$38,510,162	US\$ 37,909,471	Go
6	Madagascar, Malaria, Round 7	MDG-708-G09-M	US\$25,097,417	US\$ 16,462,000	Conditional Go
7	Afghanistan, HIV, Round 7	AFG-708-G04-H	US\$917,425	US\$ 483,579	Conditional Go
8	Afghanistan, HIV, Round 7	AFG-708-G05-H	US\$3,969,750	US\$ 3,157,640	Go
9	Zambia, TB, Round 7*	ZAM-708-G16-T	US\$25,670,852	US\$ 9,015,288	Conditional Go
10	Zambia, TB, Round 7*	ZAM-708-G18-T	US\$7,548,518	US\$ 818,664	Conditional Go
11	Zambia, Malaria, Round 7*	ZAM-708-G17-M	US\$2,437,280	US\$ 2,437,280	Conditional Go
12	Zambia, Malaria, Round 7*	ZAM-708-G19-M	US\$3,751,567	US\$ 2,379,990	Conditional Go
13	Guinea, Malaria, Round 6	GIN-607-G05-M	US\$9,639,532	US\$ 4,062,054	Conditional Go
	Total			US\$ 102,377,215	

This decision does not have material budgetary implications.